BR112012029170A2 - fármaco antimalárico que contém ácido 5-aminolevulínico ou um derivado do mesmo como um princípio ativo - Google Patents

fármaco antimalárico que contém ácido 5-aminolevulínico ou um derivado do mesmo como um princípio ativo

Info

Publication number
BR112012029170A2
BR112012029170A2 BR112012029170A BR112012029170A BR112012029170A2 BR 112012029170 A2 BR112012029170 A2 BR 112012029170A2 BR 112012029170 A BR112012029170 A BR 112012029170A BR 112012029170 A BR112012029170 A BR 112012029170A BR 112012029170 A2 BR112012029170 A2 BR 112012029170A2
Authority
BR
Brazil
Prior art keywords
derivative
active ingredient
antimalarial drug
aminolevulinic acid
drug containing
Prior art date
Application number
BR112012029170A
Other languages
English (en)
Other versions
BR112012029170B1 (pt
Inventor
Kita Kiyoshi
Nakajima Motowo
Kawata Satofumi
Kohda Takeo
Tanaka Tohro
Original Assignee
Sbi Pharmaceuticals Co Ltd
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Pharmaceuticals Co Ltd, Univ Tokyo filed Critical Sbi Pharmaceuticals Co Ltd
Publication of BR112012029170A2 publication Critical patent/BR112012029170A2/pt
Publication of BR112012029170B1 publication Critical patent/BR112012029170B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

fármaco antimalárico que contém ácido 5-aminolevulínico ou um derivado de mesmo como um princípio ativo a presente invenção refere-se a um fármaco antimalárico que é útil para a prevenção e o tratamento de doenças infecciosas causadas por parasitas causadores da malária. um agente preventivo e/ou terapêutico para malária que contém, como um princípio ativo 5-amiolevulínico (ala), um derivado do mesmo, ou um sal farmacologicamente aceitável do mesmo, é usado.
BR112012029170A 2010-05-19 2011-05-18 uso de um fármaco antimalárico que contém ácido 5-aminolevulínico ou um derivado do mesmo BR112012029170B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010115721 2010-05-19
PCT/JP2011/002770 WO2011145343A1 (ja) 2010-05-19 2011-05-18 ５－アミノレブリン酸又はその誘導体を有効成分とする抗マラリア薬

Publications (2)

Publication Number Publication Date
BR112012029170A2 true BR112012029170A2 (pt) 2017-07-18
BR112012029170B1 BR112012029170B1 (pt) 2020-05-19

Family

ID=44991461

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012029170A BR112012029170B1 (pt) 2010-05-19 2011-05-18 uso de um fármaco antimalárico que contém ácido 5-aminolevulínico ou um derivado do mesmo

Country Status (10)

Country Link
US (2) US9089530B2 (pt)
EP (1) EP2572711B1 (pt)
JP (1) JP5582441B2 (pt)
KR (2) KR20120137506A (pt)
CN (2) CN106109455A (pt)
AU (1) AU2011256661B2 (pt)
BR (1) BR112012029170B1 (pt)
CA (1) CA2799491C (pt)
NZ (1) NZ603465A (pt)
WO (1) WO2011145343A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012063487A1 (ja) * 2010-11-10 2012-05-18 国立大学法人東京工業大学 アラレマイシン又はその誘導体を有効成分とする抗マラリア薬
US9550073B2 (en) * 2011-06-16 2017-01-24 Sbi Pharmaceuticals Co., Ltd. Therapeutic agent for allergic rhinitis
JP5907357B2 (ja) 2011-10-12 2016-04-26 Ｓｂｉファーマ株式会社 移植臓器生着促進剤
HUE043511T2 (hu) * 2012-07-13 2019-08-28 Sbi Pharmaceuticals Co Ltd Immuntoleranciát kiváltó szer
EP3168296B1 (en) * 2014-07-11 2020-09-09 SBI Pharmaceuticals Co., Ltd. Agent for improving normal development rate of fertilized eggs
US10925963B2 (en) * 2015-06-22 2021-02-23 Washington University Combination artemisinin and chemiluminescent photodynamic therapy and uses therefor
CL2016003379A1 (es) * 2016-12-29 2017-08-04 Univ Santiago Chile “composición que comprende ácido delta-aminolevulínico (ala) o un derivado del mismo y oxianiones y teluro o sus derivados y su uso para el control de patógenos.”
CN109495427B (zh) * 2017-09-12 2021-05-07 腾讯科技（深圳）有限公司 多媒体数据展示方法、装置、存储介质和计算机设备
CN108635581A (zh) * 2018-05-23 2018-10-12 昆药集团股份有限公司 一种组合物及其在制备治疗肿瘤的药物中的应用
JP2022166334A (ja) * 2019-09-19 2022-11-02 国立大学法人 東京大学 鎌状赤血球症の改善及び／又は予防剤
CN113952360B (zh) * 2021-09-14 2023-03-10 上海交通大学 一种亚铁离子在治疗疟疾的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079262A (en) 1989-07-28 1992-01-07 Queen's University At Kingston Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid
US5955490A (en) * 1989-07-28 1999-09-21 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
US6710066B2 (en) * 1989-07-28 2004-03-23 Queen's University At Kingston Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins
FR2777782B1 (fr) 1998-04-22 2001-05-18 Alexandre Marti Solution pour la preparation d'une substance pharmaceutique pour le diagnostic et/ou le traitement de lesions tissulaires
ES2464169T3 (es) 2004-04-28 2014-05-30 Cosmo Oil Co., Ltd. Restaurador capilar
JP5034032B2 (ja) 2004-09-29 2012-09-26 Ｓｂｉファーマ株式会社 腫瘍診断剤
US8609073B2 (en) * 2005-03-04 2013-12-17 Dusa Pharmaceuticals, Inc. Compositions and methods for reducing photosensitivity associated with photodynamic therapy
CA2606140C (en) 2005-04-28 2011-07-19 Cosmo Oil Co., Ltd. External preparation for skin

Also Published As

Publication number Publication date
KR20120137506A (ko) 2012-12-21
KR101723834B1 (ko) 2017-04-06
CA2799491C (en) 2015-03-17
AU2011256661B2 (en) 2013-07-11
US20150283102A1 (en) 2015-10-08
US9089530B2 (en) 2015-07-28
KR20140121490A (ko) 2014-10-15
EP2572711A4 (en) 2013-11-20
JPWO2011145343A1 (ja) 2013-07-22
US9463175B2 (en) 2016-10-11
WO2011145343A1 (ja) 2011-11-24
CN102905702A (zh) 2013-01-30
CN106109455A (zh) 2016-11-16
EP2572711A1 (en) 2013-03-27
US20130108710A1 (en) 2013-05-02
EP2572711B1 (en) 2017-09-20
JP5582441B2 (ja) 2014-09-03
CA2799491A1 (en) 2011-11-24
AU2011256661A1 (en) 2012-11-29
NZ603465A (en) 2013-10-25
BR112012029170B1 (pt) 2020-05-19

Similar Documents

Publication Publication Date Title
BR112012029170A2 (pt) fármaco antimalárico que contém ácido 5-aminolevulínico ou um derivado do mesmo como um princípio ativo
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
BR112013022789A2 (pt) composições farmacêuticas que compreendem metformina e um inibidor dpp-4 ou um inibidor sglt-2
BR112017010551A2 (pt) composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento.
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
BR112012028091A2 (pt) composições farmacêuticas compreendendo pioglitazona e linagliptina
UY34974A (es) Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn
ECSP12012171A (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos
BR112015019720A2 (pt) inibidores de (benzil-ciano-metil)-amidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c
BR112012009376B8 (pt) composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
BR112012030704A2 (pt) composições farmacêuticas de cocristais de tramadol e coxibs
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
CR20150505A (es) Derivado de dihidropiridazin-3,5-diona
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
BR112015029897A2 (pt) composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
PE20151607A1 (es) Formulaciones de compuestos organicos
BR112014029597A2 (pt) compostos de cromano
BR112015025058A2 (pt) composição farmacêutica capaz de controlar facilmente o padrão de dissolução de lacosamida ou de um sal farmaceuticamente aceitável da mesma
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/05/2011, OBSERVADAS AS CONDICOES LEGAIS.